-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
p53 is a tumor suppressor gene with broad and powerful functions, and more than half of tumor patients carry p53 gene mutations
.
Mutations in the p53 gene are important drivers of tumorigenesis, progression, treatment resistance, and poor prognosis
.
p53 is a tumor suppressor gene with broad and powerful functions, and more than half of tumor patients carry p53 gene mutations
Since its discovery in 1979 , the p53 gene has been a " star molecule " in molecular biology and oncology
.
In cells, p53 can repair DNA damage and prevent cells with mutated or damaged DNA from dividing and other functions, thereby preventing the occurrence and development of cancer
.
Recently, researchers from Karolinska Institutet in Sweden published a research paper entitled: A "spindle and thread" mechanism unblocks p53 translation by modulating N-terminal disorderinStructure, a sub-journal ofCell.
In this study, the p53 protein was fused to the N -terminal domain of the native highly stable spider silk protein to construct a highly expressed and more structurally stable fusion p53 protein, which has full physiological activity in human cancer cells .
The research team hopes to eventually develop an mRNA cancer vaccine based on this discovery to treat cancers associated with p53 gene mutations
Michael Landreh, corresponding author of the study, said that p53 is a very large and disordered protein, and although powerful, the problem is that only a small amount of p53 protein is expressed in cells and then quickly broken down
.
Michael Landreh, corresponding author of the study, said that p53 is a very large and disordered protein, and although powerful, the problem is that only a small amount of p53 protein is expressed in cells and then quickly broken down
The research team fused the p53 protein to the N -terminal domain of the highly soluble spider silk protein, which showed efficient translation .
Using electron microscopy, computer simulations and mass spectrometry analysis, the research team confirmed that the fusion protein formed a compact stable conformation with the disordered transactivation domain of the p53 protein wrapped around the N -terminal domain of the spider silk protein .
Using electron microscopy, computer simulations and mass spectrometry analysis, the research team confirmed that the fusion protein formed a compact stable conformation with the disordered transactivation domain of the p53 protein wrapped around the N -terminal domain of the spider silk protein .This study shows that fusion of p53 protein to the N -terminal domain of spider silk protein helps to increase the translation level of p53 protein and increases the stability of p53 protein by forming a denser structure, and that the fusion protein is in human cancer cells .
has complete physiological activity .
has complete physiological activity .
According to the research team, this study demonstrates that reducing N -terminal disorder can overcome the inefficient translation of p53 , resulting in a protein that is conformationally stable and biologically active .
According to the research team, this study demonstrates that reducing N -terminal disorder can overcome the inefficient translation of p53 , resulting in a protein that is conformationally stable and biologically active .In this study, the fusion protein was expressed directly from synthetic mRNA , and the team said that creating a more stable p53 mutant protein in cells is a promising cancer treatment, and hopes to eventually develop a mRNA - based cancer vaccines
.
Of course, further verification of how this fused p53 protein will be processed in cells, as well as the issue of dose toxicity , is still needed
.
In this study, the fusion protein was expressed directly from synthetic mRNA , and the team said that creating a more stable p53 mutant protein in cells is a promising cancer treatment, and hopes to eventually develop a mRNA - based cancer vaccines
.
Of course, further verification of how this fused p53 protein will be processed in cells, as well as the issue of dose toxicity , is still needed
.
Paper link:
Paper link:https://doi.
org/10.
1016/j.
str.
2022.
02.
013
org/10.
1016/j.
str.
2022.
02.
013 Leave a comment here
